Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Farmers Insurance
Federal Trade Commission
Moodys
Queensland Health
Mallinckrodt
Medtronic
AstraZeneca
Cantor Fitzgerald
Boehringer Ingelheim

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,559,111

« Back to Dashboard

Summary for Patent: 5,559,111
Title: .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
Abstract:.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
Inventor(s): G oschke; Richard (Bottmingen, CH), Maibaum; J urgen K. (Weil-Haltingen, DE), Schilling; Walter (Himmelried, CH), Stutz; Stefan (Basel, CH), Rigollier; Pascal (Sierentz, FR), Yamaguchi; Yasuchika (Basel, CH), Cohen; Nissim C. (Village-Neuf, FR), Herold; Peter (Arlesheim, CH)
Assignee: Ciba-Geigy Corporation (Tarrytown, NY)
Application Number:08/416,242
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,559,111

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis AMTURNIDE aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide TABLET;ORAL 200045-001 Dec 21, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis AMTURNIDE aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide TABLET;ORAL 200045-002 Dec 21, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis AMTURNIDE aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide TABLET;ORAL 200045-003 Dec 21, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis AMTURNIDE aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide TABLET;ORAL 200045-004 Dec 21, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis AMTURNIDE aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide TABLET;ORAL 200045-005 Dec 21, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis TEKAMLO aliskiren hemifumarate; amlodipine besylate TABLET;ORAL 022545-001 Aug 26, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis TEKAMLO aliskiren hemifumarate; amlodipine besylate TABLET;ORAL 022545-002 Aug 26, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis TEKAMLO aliskiren hemifumarate; amlodipine besylate TABLET;ORAL 022545-003 Aug 26, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis TEKAMLO aliskiren hemifumarate; amlodipine besylate TABLET;ORAL 022545-004 Aug 26, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Novartis VALTURNA aliskiren hemifumarate; valsartan TABLET;ORAL 022217-001 Sep 16, 2009 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF HYPERTENSION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,559,111

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1169/94Apr 18, 1994

Non-Orange Book US Patents Family Members for Patent 5,559,111

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,659,065 Alpha-aminoalkanoic acids and reduction products ➤ Subscribe
5,606,078 3,5-Disubstituted tetrahydrofuran-2-ones ➤ Subscribe
5,627,182 .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides ➤ Subscribe
5,705,658 Azido containing tetrahydro furan compounds ➤ Subscribe
5,654,445 .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acids ➤ Subscribe
5,646,143 .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,559,111

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 183997 ➤ Subscribe
Australia 1642095 ➤ Subscribe
Australia 1642195 ➤ Subscribe
Australia 1642395 ➤ Subscribe
Australia 699616 ➤ Subscribe
Brazil 1100656 ➤ Subscribe
Canada 2147044 ➤ Subscribe
Canada 2147052 ➤ Subscribe
Canada 2147056 ➤ Subscribe
China 1117960 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Julphar
Citi
Harvard Business School
Argus Health
McKesson
Accenture
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot